Fig. 3.

JAK2/STAT3 inhibitor significantly inhibited cell motility-related cellular signaling in EGFRvIII-expressing glioblastoma cells. (A) Concentration-dependent and (B) time-dependent effect of AG490 treatment on the inhibiting activity of EGFRvIII and its downstream effectors that were crucial for cell motility in U87MG-EGFRvIII cells by Western blotting. (C) and (D) The significantly lower inhibition effect of AG490 treatment on EGFRvIII downstream effector in U87MG-vector and -EGFRwt cells compared with that in -EGFRvIII cells in (A) and (B). EGF (50 ng/mL) was added to U87MG-EGFRwt cells for 15 minutes before the cells were harvested for analysis.